[Form 4] MIRA PHARMACEUTICALS, INC. Insider Trading Activity

Rhea-AI Filing Summary

Erez Aminov, who is listed as both Chief Executive Officer and a Director of Mira Pharmaceuticals, Inc. (MIRA), reported an acquisition of 2,685,456 restricted shares of the issuer's common stock on 10/01/2025. The filing shows 3,530,156 shares beneficially owned following the transaction, held in a direct ownership form. The restricted shares were issued as compensation to Mira in connection with the company’s acquisition of SKNY Pharmaceuticals, Inc., per the explanatory note. The Form 4 is signed by Mr. Aminov on 10/03/2025.

Positive

• 2,685,456 restricted shares issued as compensation related to the SKNY Pharmaceuticals, Inc. acquisition
• Erez Aminov disclosed the transaction promptly via Form 4 and signed the filing on 10/03/2025
• Post-transaction beneficial ownership is stated as 3,530,156 shares held directly

Negative

• None.

Insights

Corporate Governance Expert

CEO received restricted shares tied to an acquisition; ownership updated.

The Form 4 discloses that Erez Aminov acquired 2,685,456 restricted shares on 10/01/2025, and beneficial ownership post-transaction is listed as 3,530,156 shares, held directly. The filing explicitly states these restricted shares were issued as compensation related to the issuer's acquisition of SKNY Pharmaceuticals, Inc..

This is a non-derivative issuance as compensation rather than a market purchase or option exercise; the timing and signature (10/03/2025) are recorded on the Form 4.

Transaction Compliance Analyst

Disclosure aligns with Section 16 reporting for insider compensation.

The report uses Transaction Code A indicating acquisition and identifies the securities as restricted shares (per explanatory note). Ownership is shown as direct, and the filing includes the required signature. No additional derivative transactions or prices are reported on this Form 4.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aminov Erez

(Last) (First) (Middle)

C/O MIRA PHARMACEUTICALS, INC.

1200 BRICKELL AVE. SUITE 1950 #1183

(Street)

MIAMI FL 33131

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MIRA PHARMACEUTICALS, INC. [ MIRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	10/01/2025	10/01/2025	A		2,685,456	A	(1)	3,530,156	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents 2,685,456 restricted shares of common stock, par value $0.0001 of the Issuer issued as compensation for the Issuer's acquisition of SKNY Pharmaceuticals, Inc.

	/s/ Erez Aminov	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did MIRA CEO Erez Aminov report on Form 4 (ticker: MIRA)?

Aminov reported acquiring 2,685,456 restricted shares on 10/01/2025, resulting in 3,530,156 shares beneficially owned.

Why were the restricted shares issued to Aminov?

The Form 4 states the 2,685,456 restricted shares were issued as compensation in connection with Mira's acquisition of SKNY Pharmaceuticals, Inc..

What form of ownership is reported for the shares?

The filing shows the shares are held directly by the reporting person.

When was the Form 4 signed and filed?

The signature block shows /s/ Erez Aminov dated 10/03/2025 and the transaction date is 10/01/2025.

Were any derivative securities reported in this Form 4?

No derivative securities (options, warrants, convertible securities) are reported on this Form 4.